



## **American Board of Psychiatry and Neurology, Inc.**

A Member Board of the American Board of Medical Specialties (ABMS)

### **CERTIFICATION EXAMINATION IN NEUROLOGY WITH SPECIAL QUALIFICATION IN CHILD NEUROLOGY**

The American Board of Psychiatry and Neurology, Inc. (ABPN) is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

The ABPN designs and develops the initial certification examination in neurology with special qualification in child neurology to assess the knowledge and reasoning skills needed to provide high quality patient care in the broad domain of the specialty. It utilizes two-dimensional content specifications. Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on fragile X syndrome could focus on treatment or systems-based practice.

The initial certification examination in neurology with special qualification in child neurology is comprised of 60% child neurology questions and 40% adult neurology questions.

Candidates should use the detailed content outline as a guide to prepare for the initial certification examination. Scores for these examinations will be reported in a standardized format.

For more information, please contact us at [questions@abpn.org](mailto:questions@abpn.org) or visit our website at [www.abpn.org](http://www.abpn.org)



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

### CERTIFICATION EXAMINATION IN NEUROLOGY WITH SPECIAL QUALIFICATION IN CHILD NEUROLOGY

#### Content Blueprint

|  |  |       |
|--|--|-------|
| <b>Number of questions: 400</b>        |  |       |
| <b>Dimension 1</b>                     |  |       |
| <b>Neurologic Disorders and Topics</b> |  |       |
| 01.                                    | Headache and pain disorders  | 7-9%  |
| 02.                                    | Epilepsy and episodic disorders  | 8-12% |
| 03.                                    | Sleep disorders  | 3-5%  |
| 04.                                    | Genetic and developmental disorders  | 8-12% |
| 05.                                    | Vascular neurology   | 2-4%  |
| 06.                                    | Neuromuscular diseases   | 8-12% |
| 07.                                    | Movement disorders   | 4-6%  |
| 08.                                    | Demyelinating diseases   | 5-7%  |
| 09.                                    | Neuroinfectious diseases   | 7-9%  |
| 10.                                    | Brain and spinal trauma and spinal diseases  | 4-6%  |
| 11.                                    | Neuro-ophthalmologic and neuro-otologic disorders  | 2-4%  |
| 12.                                    | Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents | 5-7%  |
| 13.                                    | Neuro-oncologic disorders  | 1-3%  |
| 14.                                    | Behavioral neurology and neurocognitive disorders  | 7-9%  |
| 15.                                    | Psychiatric disorders  | 4-6%  |
| 16.                                    | Autonomic nervous system disorders   | 1-2%  |
| 17.                                    | Questions not associated with a specific neurologic disorder   | 4-6%  |
| 18.                                    | Neuroimmunologic and paraneoplastic CNS disorders  | 1-3%  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

### CERTIFICATION EXAMINATION IN NEUROLOGY WITH SPECIAL QUALIFICATION IN CHILD NEUROLOGY

#### Content Blueprint

|  |        |
|--|--------|
| <b>Number of questions: 400</b>              |        |
| <b>Dimension 2</b>                           |        |
| <b>Physician Competencies and Mechanisms</b> |        |
| A. Neuroscience and mechanism of disease     | 22-28% |
| B. Clinical aspects of neurologic disease    | 17-23% |
| C. Diagnostic procedures                     | 17-23% |
| D. Treatment/Management                      | 22-28% |
| E. Interpersonal and communication skills    | 2-3%   |
| F. Professionalism                           | 2-3%   |
| G. Practice-based learning and improvement   | 2-3%   |
| H. Systems-based practice                    | 2-3%   |



# American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

## Content Outline

| <b>Dimension 1<br/>Neurologic Disorders and Topics</b>   |
|--|
| <b>01. Headache and pain disorders</b>   |
| A. Headache  |
| 01. Primary headaches  |
| a. Migraine  |
| b. Tension-type headache   |
| c. Cluster headache and other trigeminal autonomic cephalalgias  |
| d. Paroxysmal hemicrania   |
| xx. Other (exertional headache, etc.)  |
| 02. Secondary headaches  |
| a. Headache due to head and neck trauma (posttraumatic headache)   |
| b. Headache due to cranial or cervical vascular disorder (thunderclap headache, reversible cerebral vasoconstriction syndrome (RCVS), arterial dissection, cerebral hemorrhage, ischemia)          |
| c. Headache due to nonvascular intracranial disorder (hydrocephalus, idiopathic intracranial hypertension, increased intracranial pressure and cerebral edema, low-CSF-pressure headaches, tumors) |
| d. Headache due to infection   |
| e. Headache due to a substance or its withdrawal   |
| f. Headache or facial pain due to disorder of cranium, neck, eyes, ears, nose, sinuses, and teeth  |
| g. Headache due to psychiatric disorder  |
| 03. Cranial neuralgia, central and primary facial pain (trigeminal neuralgia, idiopathic facial pain, post-herpetic neuralgia)   |
| B. Pain disorders  |
| 01. Central pain syndromes (thalamic, phantom, etc.)   |
| 02. Complex regional pain syndromes  |
| <b>02. Epilepsy and episodic disorders</b>   |
| A. Generalized seizures  |
| 01. Tonic-clonic (in any combination)  |
| 02. Absence  |
| a. Typical   |
| b. Atypical  |
| c. Absence with special features   |
| 03. Myoclonic  |
| 04. Clonic   |
| 05. Tonic  |
| 06. Atonic   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| 07. Epileptic spasms  |
| 08. Negative myoclonus  |
| 09. Myoclonic-atonic  |
| B. Focal seizures   |
| 01. Preserved consciousness   |
| 02. Impaired consciousness  |
| 03. Focal to bilateral tonic-clonic   |
| XX. Other   |
| C. Electroclinical syndromes  |
| 01. Neonatal period   |
| a. Self-limited familial neonatal seizures  |
| b. Early infantile developmental and epileptic encephalopathy   |
| i. Early myoclonic encephalopathy   |
| ii. Ohtahara syndrome   |
| c. Symptomatic neonatal seizures  |
| xx. Other early infantile epileptic encephalopathy  |
| 02. Infancy   |
| a. Infantile epileptic spasms syndrome  |
| b. Myoclonic epilepsy in infancy  |
| c. Self-limited nonfamilial infantile epilepsy  |
| d. Self-limited familial infantile epilepsy   |
| e. Severe myoclonic epilepsy of infancy (Dravet syndrome)   |
| f. Myoclonic encephalopathy in nonprogressive disorders   |
| g. Epilepsy of infancy with migrating focal seizures  |
| h. Hemiconvulsion-hemiplegia-epilepsy syndrome  |
| xx. Other developmental epileptic encephalopathies with onset in infancy  |
| 03. Childhood   |
| a. Febrile seizures plus  |
| b. Self-limited epilepsy with autonomic seizures (Panayiotopoulos syndrome)   |
| c. Epilepsy with myoclonic-atonic seizures  |
| d. Self-limited epilepsy with centrotemporal spikes   |
| e. Sleep-related hypermotor (hyperkinetic) epilepsy   |
| f. Childhood occipital visual epilepsy  |
| g. Epilepsy with myoclonic absences   |
| h. Lennox-Gastaut syndrome  |
| i. Developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep (Landau-Kleffner syndrome) |
| j. Childhood absence epilepsy   |
| k. Acquired epileptic aphasia, including Landau-Kleffner syndrome   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| l. GLUT-1 syndrome  |
| m. Photosensitive occipital lobe epilepsy   |
| xx. Other developmental epileptic encephalopathies with onset in childhood              |
| 04. Adolescence through adult   |
| a. Juvenile absence epilepsy  |
| b. Juvenile myoclonic epilepsy  |
| c. Epilepsy with generalized tonic-clonic seizures alone                                |
| d. Autosomal dominant epilepsy with auditory features                                   |
| xx. Other familial temporal lobe epilepsies   |
| 05. Other benign  |
| 06. Other idiopathic  |
| 07. Other generalized/multifocal  |
| D. Less specific age relationship   |
| 01. Familial focal epilepsy with variable foci  |
| 02. Reflex epilepsies   |
| 03. Progressive myoclonus epilepsies  |
| 04. Mesial temporal lobe epilepsy with hippocampal sclerosis                            |
| 05. Rasmussen syndrome  |
| 06. Focal emotional (gelastic) seizures with hypothalamic hamartoma                     |
| E. Epilepsies attributed to and organized by structural-metabolic causes                |
| 01. Structural (including tumors, vascular malformations)                               |
| 02. Infection   |
| 03. Trauma  |
| 04. Perinatal insults   |
| 05. Malformations of cortical development (including neurocutaneous syndromes)          |
| 06. Mitochondrial and metabolic disorders   |
| 07. Stroke  |
| 08. Genetic epilepsies  |
| F. Unknown whether focal or generalized   |
| G. Conditions with epileptic seizures traditionally not diagnosed as a form of epilepsy |
| 01. Benign neonatal seizures  |
| 02. Febrile seizures  |
| 03. Provoked seizures   |
| 04. Eclampsia   |
| 05. Single unprovoked seizures  |
| H. Nonepileptic paroxysmal disorders  |
| 01. Syncope and anoxic seizures   |
| 02. Functional seizures and other behavioral, psychological, and psychiatric disorders  |
| 03. Sleep-related conditions  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| 04. Paroxysmal movement disorders           |
| 05. Migraine-associated disorders           |
| 06. Miscellaneous events                    |
| XX. Other                                   |
| I. Status epilepticus                       |
| 01. Convulsive                              |
| 02. Nonconvulsive                           |
| 03. Focal motor                             |
| 04. Tonic status                            |
| 05. Febrile                                 |
| 06. Refractory and super-refractory         |
| XX. Unknown                                 |
| <b>03. Sleep disorders</b>                  |
| A. Insomnia                                 |
| 01. Psychological insomnia                  |
| 02. Inadequate sleep hygiene                |
| B. Sleep-disordered breathing               |
| 01. Obstructive sleep apnea                 |
| 02. Central apnea syndromes                 |
| 03. Sleep-related hypoventilation disorders |
| C. Central disorders of hypersomnolence     |
| 01. Narcolepsy (with and without cataplexy) |
| 02. Kleine-Levin syndrome                   |
| 03. Hypersomnia due to a medical condition  |
| 04. Insufficient sleep syndrome             |
| D. Circadian rhythm sleep-wake disorders    |
| 01. Delayed sleep-wake phase disorder       |
| 02. Advanced sleep-wake phase disorder      |
| 03. Irregular sleep-wake rhythm disorder    |
| 04. Non-24-hour sleep-wake phase disorder   |
| E. Parasomnias                              |
| 01. Non-REM-related parasomnias             |
| a. Arousal disorders                        |
| i. Sleepwalking                             |
| ii. Sleep terrors                           |
| iii. Confusional arousals                   |
| b. Sleep-related eating disorder            |
| 02. REM-related parasomnias                 |
| a. REM sleep behavior disorder              |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| b. Recurrent isolated sleep paralysis  |
| c. Nightmare disorder  |
| 03. Other  |
| a. Exploding head syndrome   |
| b. Sleep-related hallucinations  |
| c. Sleep enuresis  |
| d. Parasomnia due to a general medical disorder  |
| e. Medication/substance-related parasomnia   |
| f. Unspecified parasomnia  |
| F. Sleep-related movement disorders  |
| 01. Periodic limb movements of sleep   |
| 02. Sleep-related limb cramps  |
| 03. Sleep-related bruxism  |
| 04. Benign myoclonus of infancy  |
| G. Sleep disorders in other conditions   |
| 01. Sleep disturbances in movement conditions  |
| a. Parkinson disease   |
| b. Multisystem atrophy   |
| c. Dementia with Lewy bodies   |
| d. Spinocerebellar degeneration  |
| e. Huntington disease  |
| 02. Neuromuscular disorders (amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophy, and others) |
| 03. Alzheimer disease  |
| 04. Effects of sleep disorders on cardiovascular/cerebrovascular risk factors                                  |
| a. Hypertension  |
| b. Atrial fibrillation   |
| c. Congestive heart failure  |
| d. Myocardial infarction   |
| e. Stroke  |
| <b>04. Genetic and developmental disorders</b>   |
| A. Heritable disorders of metabolism   |
| 01. Disorders of amino acid metabolism and transport   |
| a. Phenylketonuria   |
| b. Nonketotic hyperglycinemia (glycine encephalopathy)   |
| c. Maple syrup urine disease   |
| d. Homocystinuria  |
| e. Tyrosinemia   |
| f. Hartnup disease   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| xx. Other  |
| 02. Disorders of organic acid metabolism   |
| a. Methylmalonic acidemia  |
| b. Propionic acidemia  |
| c. Glutaric acidemia   |
| xx. Other  |
| 03. Disorders of urea metabolism   |
| a. Ornithine transcarbamylase deficiency   |
| b. N-acetylglutamate synthase deficiency   |
| c. Carbamoyl phosphate synthetase 1 deficiency                                     |
| d. Citrullinemia   |
| e. Argininosuccinic aciduria   |
| f. Argininemia   |
| g. Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome               |
| xx. Other  |
| 04. Disorders of monosaccharide metabolism and transport                           |
| a. Galactosemia  |
| b. Glucose transporter deficiency  |
| c. Other   |
| 05. Mitochondrial disorders  |
| a. Myoclonic epilepsy with ragged red fibers (MERRF)                               |
| b. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) |
| c. Kearns-Sayre syndrome   |
| d. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)                   |
| e. Leigh syndrome  |
| f. Leber hereditary optic neuropathy   |
| g. Progressive external ophthalmoplegia  |
| xx. Other  |
| 06. Peroxisomal disorders  |
| a. Zellweger syndrome  |
| b. Adrenoleukodystrophy and adrenomyeloneuropathy                                  |
| c. Other   |
| 07. Disorders of purine metabolism   |
| a. Lesch-Nyhan syndrome  |
| b. Other   |
| 08. Lysosomal disorders  |
| a. Glycogen storage diseases   |
| i. Pompe disease (Type II; acid maltase deficiency)                                |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| ii. Other   |
| b. Mucopolysaccharidoses                                  |
| i. Hunter syndrome  |
| ii. Hurler syndrome                                       |
| iii. Sanfilippo syndrome                                  |
| iv. Morquio syndrome                                      |
| v. Maroteaux-Lamy syndrome                                |
| xx. Other   |
| c. Sphingolipidoses and gangliosidoses                    |
| i. GM1 gangliosidosis                                     |
| ii. Tay-Sachs disease (early onset GM2 gangliosidosis)    |
| iii. Sandhoff disease (late onset GM2 gangliosidosis)     |
| iv. Fabry disease   |
| v. Niemann Pick disease                                   |
| vi. Gaucher disease                                       |
| vii. Krabbe disease                                       |
| viii. Metachromatic leukodystrophy                        |
| xx. Other   |
| 09. Other genetic disorders                               |
| a. Pelizaeus-Merzbacher disease                           |
| b. Alexander disease                                      |
| c. Canavan disease  |
| d. Porphyria  |
| e. Disorders of iron metabolism (e.g., PKAN)              |
| f. Disorders of copper metabolism (e.g., Wilson disease)  |
| g. Disorders of neurotransmitter metabolism (e.g., SSADH) |
| h. Neuronal ceroid lipofuscinosis                         |
| i. Disorders of cholesterol metabolism                    |
| xx. Other   |
| XX. Other   |
| B. Chromosomal disorders                                  |
| 01. Autosomal abnormalities                               |
| a. Down syndrome (trisomy 21)                             |
| b. Trisomy 13   |
| c. Cri du chat syndrome                                   |
| d. Uniparental disomy syndromes                           |
| i. Angelman syndrome                                      |
| ii. Prader-Willi syndrome                                 |
| iii. Other  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| e. Williams syndrome   |
| f. 22q11.2 deletion syndrome (DiGeorge syndrome)                                     |
| xx. Other  |
| 02. X-chromosomal disorders  |
| a. Fragile X syndrome  |
| b. Turner syndrome   |
| c. Other   |
| 03. Other  |
| C. Sporadic, gene-related disorders  |
| 01. Rett syndrome  |
| 02. Other  |
| D. Developmental disorders of skull and brain structure                              |
| 01. Anencephaly  |
| 02. Encephalocele  |
| 03. Cerebellar and brainstem malformations   |
| a. Chiari malformations  |
| b. Cerebellar hypoplasia   |
| c. Joubert syndrome  |
| d. Dandy Walker and related variants   |
| xx. Other  |
| 04. Cerebral malformations   |
| a. Holoprosencephaly   |
| b. Septo-optic dysplasia   |
| c. Schizencephaly  |
| d. Migrational abnormalities (including lissencephaly)                               |
| e. Agenesis of the corpus callosum   |
| f. Hemimegalencephaly  |
| xx. Other  |
| 05. Abnormalities of brain and/or head size  |
| a. Microencephaly and microcephaly   |
| b. Macroencephaly and macrocephaly (including related systemic overgrowth syndromes) |
| c. Other   |
| 06. Abnormalities of brain CSF spaces  |
| a. Hydrocephalus   |
| b. Cystic malformations (including arachnoid, colloid, pineal, dermoid, epidermoid)  |
| c. Other   |
| 07. Spinal cord malformations (dysraphism)   |
| a. Syringomyelia   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| b. Diastematomyelia  |
| c. Tethered cord   |
| xx. Other  |
| E. Neurocutaneous syndromes  |
| 01. Neurofibromatosis 1 and 2  |
| 02. Tuberous sclerosis   |
| 03. Sturge-Weber syndrome  |
| 04. Ataxia-telangiectasia  |
| 05. Von Hippel-Lindau disease  |
| 06. Incontinentia pigmenti   |
| XX. Other  |
| F. Cerebral palsy  |
| 01. Spastic cerebral palsy   |
| 02. Dyskinetic/dystonic cerebral palsy                                 |
| 03. Ataxic cerebral palsy  |
| XX. Other  |
| G. Teratogens  |
| H. Multiple congenital anomalies                                       |
| XX. Other  |
| <b>05. Vascular neurology</b>  |
| A. Ischemic stroke (cerebral infarction and transient ischemic attack) |
| 01. Atherosclerosis  |
| a. Large-artery  |
| b. Small-artery  |
| 02. Cardioembolic  |
| 03. Arterial dissection  |
| 04. Other vasculopathies, including vasculitis                         |
| a. Noninflammatory   |
| b. Infectious  |
| c. Inflammatory  |
| 05. Spinal cord infarction/ischemia                                    |
| XX. Other  |
| B. Intracerebral hemorrhage  |
| 01. Chronic hypertension   |
| 02. Vascular malformations   |
| 03. Bleeding diatheses and antithrombotic agents                       |
| 04. Cerebral amyloid angiopathy  |
| 05. Hemorrhagic tumors   |
| 06. Pituitary apoplexy   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| 07. Locations of intracerebral hemorrhage  |
| XX. Other  |
| C. Subarachnoid hemorrhage   |
| 01. Aneurysm   |
| 02. Vascular malformations   |
| 03. Complications (including vasospasm)  |
| 04. Trauma   |
| D. Cerebral venous thrombosis  |
| 01. Pregnancy and puerperium   |
| 02. Hypercoagulability (thrombophilia)   |
| 03. Cavernous sinus thrombosis   |
| XX. Other  |
| E. Reversible cerebrovascular constriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) |
| F. Sickle cell disease   |
| G. Unruptured brain aneurysm or unruptured vascular malformation   |
| H. CADASIL   |
| I. Primary intraventricular hemorrhage   |
| J. Carotid cavernous or dural fistulas   |
| K. Cardiovascular diseases   |
| L. Stroke genetics   |
| M. Prothrombotic (hypercoagulable) causes of stroke  |
| N. Hypoxic-ischemic encephalopathy   |
| XX. Other  |
| <b>06. Neuromuscular diseases</b>  |
| A. Motor neuron disorders  |
| 01. Sporadic   |
| a. Amyotrophic lateral sclerosis   |
| i. Progressive muscular atrophy  |
| ii. Primary lateral sclerosis  |
| iii. Progressive bulbar palsy  |
| 02. Genetic  |
| a. Familial amyotrophic lateral sclerosis  |
| b. Spinal muscular atrophy   |
| c. Spinobulbar muscular atrophy (Kennedy disease)  |
| d. Tay-Sachs disease   |
| e. Distal hereditary motor neuropathy  |
| 03. Focal, including monomelic amyotrophy (Hirayama disease)   |
| 04. Paraneoplastic   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| 05. Toxic  |
| a. Lathyrism   |
| 06. Infectious   |
| a. Polio   |
| b. Rabies  |
| c. West Nile virus   |
| d. Tetanus   |
| e. Enterovirus D68 (EV-D68)  |
| B. Spinal root disorders   |
| 01. Cervical   |
| 02. Thoracic   |
| 03. Lumbosacral  |
| 04. Polyradiculopathy  |
| 05. Myeloneuropathy  |
| C. Plexopathies  |
| 01. Brachial   |
| a. Traumatic (neonatal, penetrating injury)                        |
| b. Radiation-induced   |
| c. Neuralgic amyotrophy (brachial neuritis)                        |
| d. Hereditary neuralgic amyotrophy                                 |
| e. Neoplastic  |
| f. Neurogenic thoracic outlet syndrome                             |
| xx. Other  |
| 02. Lumbosacral  |
| a. Traumatic (hematoma, ischemic)                                  |
| b. Radiation-induced   |
| c. Diabetic radiculoplexus neuropathy                              |
| d. Neoplastic  |
| xx. Other  |
| D. Peripheral nerve disorders                                      |
| 01. Mononeuropathies   |
| 02. Mononeuropathy multiplex                                       |
| 03. Polyneuropathy   |
| a. Hereditary  |
| i. Demyelinating   |
| (a) CMT1a  |
| (b) CMTX   |
| (c) Hereditary neuropathy with tendencies to pressure palsy (HNPP) |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| (d) Refsum disease  |
| (e) Metachromatic leukodystrophy  |
| ii. Axon loss   |
| (a) CMT2  |
| (b) Adrenoleukodystrophy  |
| iii. TTR amyloid polyneuropathy   |
| iv. Porphyric neuropathy  |
| b. Acquired   |
| i. Immune mediated  |
| (a) Guillain-Barré syndrome   |
| (i) Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)              |
| (ii) Miller Fisher variant (GQ1b antibody)                                      |
| (iii) Acute motor axonal neuropathy   |
| (iv) Acute motor and sensory axonal neuropathy                                  |
| (v) Pharyngeal-cervical-brachial  |
| (b) Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)            |
| (c) Multifocal mononeuropathy with conduction block                             |
| (d) Distal acquired demyelinating symmetric neuropathy (DADS)                   |
| (e) Multifocal acquired demyelinating sensory and motor polyneuropathy (MADSAM) |
| (f) Paraneoplastic  |
| (g) Amyloidosis   |
| (h) Sarcoidosis   |
| (i) Paraproteinemic   |
| ii. Metabolic   |
| (a) Diabetic  |
| (b) Nutritional   |
| (i) Vitamin B6 deficiency   |
| (ii) Vitamin B12 deficiency   |
| (iii) Copper deficiency   |
| (iv) Alcohol  |
| (v) Hypervitaminosis B6   |
| (xx) Other  |
| (c) Critical illness  |
| iii. Toxic  |
| (a) Arsenic, lead, thallium   |
| (b) n-Hexane  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| (c) Organophosphates                                     |
| (d) Drug-induced   |
| (xx) Other   |
| iv. Infectious   |
| (a) Diphtheria   |
| (b) HIV  |
| (c) Leprosy  |
| (d) Lyme disease   |
| (e) Syphilis   |
| (xx) Other   |
| c. Dorsal root ganglion disorders                        |
| i. Nutritional/toxic, including hypervitaminosis B6      |
| ii. Autoimmune/inflammatory                              |
| (a) Hu antibody syndrome                                 |
| (b) Connective tissue disease (Sjögren syndrome)         |
| iii. Friedreich ataxia                                   |
| iv. Idiopathic   |
| d. Small fiber neuropathy                                |
| E. Neuromuscular junction transmission disorders         |
| 01. Myasthenia gravis                                    |
| 02. Lambert-Eaton myasthenic syndrome                    |
| 03. Botulism   |
| 04. Congenital/hereditary myasthenia                     |
| 05. Medication-induced                                   |
| XX. Other  |
| F. Muscle disorders                                      |
| 01. Hereditary   |
| a. Muscular dystrophies                                  |
| i. Duchenne/Becker                                       |
| ii. Facioscapulohumeral                                  |
| iii. Limb-girdle   |
| (a) Type 1   |
| (b) Type 2   |
| iv. Myotonic   |
| (a) Myotonic dystrophy 1 (including distal presentation) |
| (b) Myotonic dystrophy 2                                 |
| v. Oculopharyngeal                                       |
| vi. Myofibrillar (including distal presentation)         |
| vii. Congenital muscular dystrophy                       |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| b. Congenital myopathies                                      |
| i. Central core   |
| ii. Nemaline  |
| iii. Centronuclear/myotubular (including distal presentation) |
| xx. Other   |
| c. Metabolic myopathies                                       |
| i. Mitochondrial  |
| (a) Myoclonic epilepsy with ragged red fibers (MERRF)         |
| (b) Mitochondrial myopathy, lactic acid, and stroke (MELAS)   |
| (c) Kearns-Sayre syndrome                                     |
| (xx) Other  |
| ii. Glycogenoses  |
| (a) Pompe disease/Acid maltase deficiency                     |
| (b) Myophosphorylase deficiency (McArdle disease)             |
| (c) Other   |
| iii. Lipidoses  |
| (a) Carnitine deficiency                                      |
| (b) Carnitine palmitoyltransferase 2 deficiency (CPT2)        |
| (c) Other   |
| d. Periodic paralyses/channelopathies                         |
| i. Hypokalemic  |
| ii. Hyperkalemic  |
| iii. Andersen-Tawil syndrome                                  |
| iv. Nondystrophic myotonias                                   |
| 02. Acquired  |
| a. Inflammatory myopathies                                    |
| i. Polymyositis   |
| ii. Dermatomyositis   |
| iii. Inclusion body myositis                                  |
| (a) Sporadic (including distal presentation)                  |
| (b) Hereditary (including distal presentation)                |
| iv. Sarcoidosis   |
| v. HIV  |
| b. Critical illness myopathy                                  |
| c. Toxic/drug-induced myopathy                                |
| i. HMG-CoA reductase  |
| ii. Alcohol   |
| iii. Chloroquine/hydroxychloroquine                           |
| iv. Corticosteroids   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| v. Colchicine   |
| vi. Antiretroviral medications  |
| d. Metabolic/endocrine  |
| i. Hypothyroid  |
| ii. Hyperthyroid  |
| iii. Hypokalemic  |
| iv. Cushing disease   |
| e. Necrotizing autoimmune myopathy  |
| i. Anti-HMG-CoA reductase myopathy  |
| ii. Anti-signal recognition particle (anti-SRP)                                     |
| 03. Rhabdomyolysis  |
| 04. Abnormalities of muscle tone  |
| a. Hypotonia  |
| b. Spasticity   |
| c. Rigidity   |
| G. Hyper-excitability disorders   |
| 01. Stiff-person syndrome   |
| 02. Potassium channelopathies (including Isaacs syndrome)                           |
| H. Autonomic dysfunction in neuromuscular diseases                                  |
| 01. Autoimmune autonomic neuropathy and ganglionopathy (including Sjögren syndrome) |
| 02. Guillain-Barré syndrome (autonomic manifestations)                              |
| 03. Paraneoplastic autonomic neuropathies   |
| 04. Fabry disease   |
| 05. Autonomic neuropathies due to infectious disease                                |
| a. American trypanosomiasis Chagas disease  |
| b. Leprosy  |
| c. Diphtheria   |
| d. HIV  |
| 06. Diabetes (autonomic manifestations)   |
| 07. Amyloidosis   |
| 08. Tonic pupil (Adie syndrome)   |
| 09. Small fiber polyneuropathy (autonomic manifestations)                           |
| 10. Toxic neuropathies  |
| a. Vacor  |
| b. Hexane   |
| c. Ciguatoxin   |
| d. Vincristine  |
| e. Cisplatin, paclitaxel  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| f. Heavy metals (e.g., arsenic, mercury, thallium)  |
| g. Postural orthostatic tachycardia syndrome (POTS) |
| xx. Other   |
| XX. Other   |
| <b>07. Movement disorders</b>                       |
| A. Parkinson disease and parkinsonism               |
| 01. Neurodegenerative                               |
| a. Idiopathic Parkinson disease                     |
| i. Dementia with Lewy bodies                        |
| b. Multiple system atrophy                          |
| c. Progressive supranuclear palsy                   |
| d. Corticobasal degeneration                        |
| 02. Posttraumatic parkinsonism                      |
| 03. Vascular parkinsonism                           |
| 04. Drug-induced parkinsonism                       |
| 05. Hydrocephalus and normal-pressure hydrocephalus |
| 06. Juvenile parkinsonism                           |
| B. Tremor   |
| 01. Essential tremor                                |
| 02. Physiological tremor                            |
| 03. Drug-induced tremor                             |
| C. Chorea   |
| 01. Huntington disease                              |
| 02. Sydenham chorea                                 |
| 03. Drug-induced chorea                             |
| 04. Chorea gravidarum                               |
| 05. Neuroacanthocytosis                             |
| D. Ballism and athetosis                            |
| E. Dystonia   |
| 01. Focal dystonia                                  |
| a. Genetic  |
| b. Nongenetic                                       |
| 02. Generalized dystonia                            |
| a. Genetic  |
| b. Nongenetic                                       |
| 03. Dopa-responsive dystonia                        |
| XX. Other   |
| F. Hepatolenticular degeneration (Wilson disease)   |
| G. Neuroleptic-induced syndromes, acute and chronic |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| 01. Acute dystonic reaction                          |
| 02. Tardive syndromes                                |
| H. Tic disorders                                     |
| 01. Tourette syndrome                                |
| 02. Other  |
| I. Myoclonus   |
| 01. Essential myoclonus                              |
| 02. Post-hypoxic myoclonus                           |
| J. Other paroxysmal disorders                        |
| 01. Hemifacial spasm                                 |
| 02. Dyskinesias                                      |
| 03. Restless legs syndrome                           |
| 04. Automatisms                                      |
| 05. Stereotypies                                     |
| K. Ataxia  |
| 01. Spinocerebellar ataxias                          |
| 02. Friedreich ataxia                                |
| 03. Vitamin  |
| 04. Paroxysmal ataxia                                |
| L. Functional movement disorders                     |
| 01. Tremor   |
| 02. Dystonia   |
| 03. Gait disturbance and ataxia                      |
| M. Critical care                                     |
| 01. Acute parkinsonism                               |
| 02. Neuroleptic malignant syndrome                   |
| 03. Serotonin syndrome                               |
| 04. Dystonic storm                                   |
| 05. Ballism  |
| 06. Tic status                                       |
| <b>08. Demyelinating diseases</b>                    |
| A. Multiple sclerosis and variants                   |
| B. Neuromyelitis optica                              |
| C. Acute disseminated encephalomyelitis and variants |
| D. Transverse myelitis                               |
| XX. Other  |
| <b>09. Neuroinfectious diseases</b>                  |
| A. Bacterial infections                              |
| 01. Meningitis                                       |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| a. Neonatal  |
| i. E. coli   |
| ii. Streptococcus  |
| iii. Listeria  |
| xx. Other  |
| b. Childhood   |
| i. Hemophilus influenza  |
| ii. Streptococcus pneumonia  |
| iii. Other   |
| c. Adolescent  |
| i. Neisseria meningitis  |
| ii. Other  |
| d. Adult   |
| i. Streptococcus pneumonia   |
| ii. Listeria   |
| iii. Other   |
| 02. Brain and spine abscesses (Epidural and subdural abscesses including disc space infection, osteomyelitis, and empyema) |
| 03. Congenital   |
| B. Fungal infections   |
| 01. Meningitis   |
| a. Cryptococcus  |
| b. Histoplasmosis  |
| c. Coccidiomycosis   |
| xx. Other  |
| 02. Cerebritis   |
| a. Aspergillosis   |
| b. Phycomycosis  |
| c. Other   |
| 03. Congenital   |
| C. Mycobacteria, including tuberculosis  |
| D. Viral infections  |
| 01. Meningitis   |
| 02. Encephalitis and myelitis  |
| a. West Nile virus   |
| b. Herpesvirus   |
| i. Simplex   |
| ii. Varicella zoster   |
| iii. HHV-6   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| iv. Cytomegalovirus  |
| xx. Other  |
| c. Arbovirus   |
| d. Rabies  |
| e. HIV   |
| f. Progressive multifocal leukoencephalopathy  |
| g. Polio   |
| i. Acute flaccid paralysis/Polio-like syndrome   |
| h. Measles   |
| xx. Other  |
| 03. Congenital   |
| E. Protozoan infections  |
| 01. Toxoplasmosis  |
| 02. Naegleria  |
| 03. Trypanosomiasis  |
| XX. Other  |
| F. Parasitic infections  |
| 01. Cysticercosis  |
| 02. Malaria  |
| 03. Congenital   |
| XX. Other  |
| G. Prion infections [e.g., subacute spongiform encephalopathy (Creutzfeldt-Jakob disease), others] |
| H. Noninfectious causes of meningitis  |
| I. Systemic infections with neurologic effects   |
| 01. Lyme disease   |
| 02. Syphilis   |
| 03. Diphtheria   |
| 04. Tetanus  |
| 05. Intestinal lipodystrophy (Whipple disease)   |
| 06. Leprosy  |
| XX. Other  |
| <b>10. Brain and spinal trauma and spinal cord disorders</b>                                       |
| A. Brain trauma  |
| 01. Cerebral concussion, including chronic traumatic encephalopathy                                |
| 02. Diffuse axonal injury  |
| 03. Cerebral contusion   |
| 04. Traumatic hemorrhage   |
| a. Epidural hematoma   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| b. Subdural hematoma   |
| c. Traumatic subarachnoid hemorrhage                               |
| 05. Increased intracranial pressure and herniation syndromes       |
| B. Spinal trauma   |
| 01. Spinal cord contusion and transection                          |
| 02. Spinal epidural hematoma                                       |
| C. Nontraumatic spinal cord disorders                              |
| 01. Spinal cord/myelopathy (e.g., compression, other)              |
| 02. Spinal cord herniation   |
| 03. Associated autonomic disorders                                 |
| 04. Cauda equina (e.g., compression, other)                        |
| 05. Spinal cord infarction   |
| 06. Vascular myelopathies  |
| 07. Spinal cord vascular malformations                             |
| XX. Other (e.g., hereditary spastic paraparesis)                   |
| D. Abusive head trauma   |
| E. Myeloneuropathy   |
| <b>11. Neuro-ophthalmologic and neuro-otologic disorders</b>       |
| A. Neuro-ophthalmology   |
| 01. Disorders of the optic nerve                                   |
| a. Vascular (e.g., anterior ischemic optic neuropathy)             |
| b. Inflammatory (e.g., optic neuritis)                             |
| c. Toxic and nutritional optic nerve disease                       |
| d. Inherited (e.g., Leber optic atrophy)                           |
| e. Papilledema and pseudopapilledema                               |
| f. Optic nerve tumor   |
| 02. Disorders of the retina  |
| a. Retinal artery occlusion, including Susac syndrome              |
| b. Retinal venous occlusion  |
| c. Retinal degenerations   |
| d. Phakomatoses  |
| 03. Other lesions of optic pathways                                |
| a. Optic chiasm  |
| b. Optic tracts  |
| c. Optic radiations  |
| d. Visual cortex, including visual agnosias and cortical blindness |
| 04. Disorders of the pupil   |
| a. Horner syndrome   |
| b. Argyll-Robertson pupil  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| c. Tonic pupil (Adie syndrome)  |
| 05. Disorders of ocular motility  |
| a. Disorders of supranuclear control of eye movements   |
| i. Horizontal gaze paresis, including internuclear ophthalmoplegia and one-and-a-half syndrome                        |
| ii. Upgaze paresis (e.g., Parinaud syndrome)  |
| iii. Downgaze paresis   |
| b. Disorders of cranial nerves 3,4, 6, and their nuclei   |
| c. Nystagmus  |
| d. Cavernous sinus disorders  |
| e. Extraocular disorders  |
| f. Electroclinical syndromes  |
| g. Cerebral/cortical visual impairment  |
| h. Strabismus   |
| i. Congenital cataracts   |
| j. Congenital glaucoma  |
| xx. Other   |
| 06. Intraocular manifestations of stroke  |
| B. Neuro-otology  |
| 01. Vestibular disease  |
| a. Benign paroxysmal positional vertigo   |
| b. Idiopathic endolymphatic hydrops (Ménière disease)   |
| c. Acute labyrinthitis  |
| d. Toxic vestibulopathy   |
| e. Cerebellopontine angle tumors  |
| f. Central vertigo, including disembarkment syndrome  |
| g. Benign paroxysmal vertigo of childhood   |
| h. Acute vestibular syndrome  |
| 02. Hearing loss, including inherited and acquired  |
| a. Sensorineural  |
| b. Conductive   |
| c. Central auditory processing disorder   |
| 03. Carotid body tumors (chemodectomas/paragangliomas)  |
| XX. Other, including pulsatile tinnitus   |
| <b>12. Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents</b> |
| A. Metabolic diseases   |
| 01. Hypoxic-ischemic encephalopathy   |
| 02. Disorders of glucose metabolism, including hypoglycemia, diabetic ketoacidosis, and nonketotic hyperglycemia      |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| 03. Hepatic encephalopathy   |
| 04. Uremic encephalopathy, including dialysis dementia and dialysis dysequilibrium syndrome                                    |
| 05. Disorders of sodium, potassium, and water metabolism, including hyponatremia, hypernatremia, hypokalemia, and hyperkalemia |
| 06. Disorders of calcium and magnesium metabolism, including hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia  |
| 07. Endocrine diseases, including those of thyroid, parathyroid, adrenal, and pituitary glands (including pituitary apoplexy)  |
| 08. Drug overdose  |
| 09. Hyperbilirubinemia   |
| <b>B. Nutritional deficiency states</b>  |
| 01. B vitamins   |
| a. Thiamine (including Wernicke encephalopathy)  |
| b. Niacin  |
| c. Pyridoxine  |
| d. Cobalamin   |
| e. Folic acid  |
| f. Biotin  |
| 02. Vitamin E  |
| 03. Vitamins A and D   |
| 04. Copper   |
| 05. Protein calorie malnutrition   |
| 06. Strachan syndrome and related disorders  |
| 07. Complications of bariatric surgery   |
| XX. Other  |
| <b>C. Toxins, drugs, and physical agents</b>   |
| 01. Exposure to chemicals  |
| a. Acrylamide  |
| b. Carbon disulfide  |
| c. Ethylene oxide  |
| d. Hexacarbon solvents   |
| e. Organophosphates  |
| f. Toluene   |
| g. Carbon monoxide   |
| xx. Other  |
| 02. Exposure to metals   |
| a. Aluminum  |
| b. Arsenic   |
| c. Lead  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| d. Manganese   |
| e. Mercury   |
| f. Thallium  |
| g. Tin   |
| xx. Other  |
| 03. Effects of drug abuse  |
| a. Opioids   |
| b. Cocaine   |
| c. Amphetamines  |
| d. Sedative-hypnotics  |
| e. Inhalants   |
| f. Hallucinogens   |
| xx. Other  |
| 04. Effects of alcohol   |
| a. Acute alcoholic intoxication  |
| b. Alcohol withdrawal syndromes  |
| c. Effects related to nutritional deficiency   |
| d. Effects of unknown etiology (e.g., Marchiafava-Bignami disease)                   |
| e. Effects of alcohols other than ethanol (e.g., methyl alcohol and ethylene glycol) |
| f. Fetal exposure to alcohol   |
| 05. Effects of ionizing radiation  |
| a. Encephalopathy  |
| b. Myelopathy  |
| c. Plexopathy  |
| 06. Hypothermia and hyperthermia   |
| 07. Electric current and lightning   |
| 08. Animal and insect neurotoxins  |
| a. Snakes  |
| b. Spiders   |
| c. Scorpions   |
| d. Ticks   |
| 09. Marine neurotoxins   |
| a. Ciguatera fish  |
| b. Puffer fish   |
| 10. Plant neurotoxins  |
| a. Mushrooms   |
| b. Other   |
| D. Iatrogenic/therapeutic drugs  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| <b>13. Neuro-oncologic disorders</b>       |
| A. Neoplasms                               |
| 01. Primary                                |
| a. Primitive neuroectodermal tumors        |
| i. Medulloblastoma                         |
| ii. Retinoblastoma                         |
| b. Gliomas                                 |
| i. Astrocytoma                             |
| (a) Low-grade                              |
| (i) Pilocytic astrocytoma                  |
| (ii) Astrocytoma                           |
| (b) High-grade                             |
| (i) Anaplastic astrocytoma                 |
| (ii) Glioblastoma                          |
| ii. Oligodendroglioma                      |
| (a) Oligodendroglioma                      |
| (b) Anaplastic oligodendroglioma           |
| iii. Ependymoma                            |
| (a) Ependymoma                             |
| (b) Anaplastic ependymoma                  |
| (c) Myxopapillary ependymoma               |
| c. Neuronal tumors                         |
| i. Central neurocytoma                     |
| ii. Dysembryoplastic neuroectodermal tumor |
| iii. Gangliocytoma                         |
| iv. Ganglioglioma                          |
| d. Meningioma                              |
| e. Nerve sheath tumors                     |
| i. Schwannoma                              |
| ii. Neurofibroma                           |
| f. Primary CNS lymphoma                    |
| g. Craniopharyngioma                       |
| h. Pituitary adenoma                       |
| i. Pineal tumors                           |
| j. Choroid plexus tumors                   |
| k. Hypothalamic tumors                     |
| xx. Other                                  |
| 02. Secondary                              |
| a. Metastatic intraparenchymal             |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| b. Meningeal carcinomatosis  |
| c. Metastases to spine and skull   |
| B. Hereditary tumor syndromes  |
| 01. Neurofibromatosis  |
| 02. Von Hippel-Lindau disease  |
| 03. Tuberous sclerosis   |
| 04. Cowden syndrome  |
| 05. Multiple endocrine neoplasms   |
| C. Nonmetastatic neurologic complications of systemic cancer                                 |
| 01. Vascular disease   |
| D. Neurologic complications of cancer treatment  |
| 01. Radiation therapy  |
| a. Radiation necrosis  |
| b. Secondary neoplasms   |
| 02. Chemotherapy   |
| <b>14. Behavioral neurology and neurocognitive disorders</b>                                 |
| A. Delirium, dementia, and other cognitive disorders   |
| 01. Delirium   |
| a. Delirium due to a medical condition   |
| b. Substance intoxication delirium   |
| c. Substance withdrawal delirium   |
| d. Delirium due to multiple etiologies   |
| xx. Other  |
| 02. Dementia   |
| a. Mild cognitive impairment   |
| b. Alzheimer disease   |
| c. Vascular dementia   |
| d. HIV   |
| e. Traumatic brain injury  |
| f. Frontotemporal disorders  |
| g. Dementia due to a medical condition   |
| h. Substance/medication-induced dementia   |
| i. Multiple etiologies, including metabolic, endocrine, toxic, and neoplastic/paraneoplastic |
| j. Primary progressive aphasia   |
| k. Dementia with Lewy bodies   |
| l. Cerebral small vessel disease   |
| xx. Other  |
| 03. Amnestic disorders (including transient global amnesia)                                  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| XX. Other  |
| B. Neurodevelopmental disorders                                  |
| 01. Learning disorders   |
| 02. Communication disorders                                      |
| 03. Autism spectrum disorder                                     |
| 04. Attention-deficit and disruptive behavior disorders          |
| 05. Cognitive impairment   |
| a. Global developmental delay                                    |
| b. Intellectual developmental disorder (intellectual disability) |
| XX. Other  |
| C. Higher cortical function and clinical syndromes               |
| 01. Frontal lobe syndromes                                       |
| 02. Aphasia  |
| 03. Apraxia  |
| 04. Neglect  |
| 05. Agnosia  |
| 06. Disconnection syndromes                                      |
| XX. Other  |
| D. Alteration of mental status/encephalopathy/coma/brain death   |
| E. Pseudobulbar affect/pseudobulbar palsy                        |
| XX. Other  |
| <b>15. Psychiatric disorders</b>                                 |
| A. Schizophrenia and other psychotic disorders                   |
| 01. Schizophrenia  |
| 02. Brief psychotic disorder                                     |
| 03. Psychotic disorder due to another medical condition          |
| 04. Substance/medication-induced psychotic disorder              |
| 05. Catatonia  |
| XX. Other  |
| B. Depressive disorders  |
| 01. Major depressive disorder                                    |
| 02. Persistent depressive disorder (dysthymia)                   |
| 03. Depressive disorder due to another medical condition         |
| XX. Other  |
| C. Bipolar and related disorders                                 |
| 01. Bipolar I disorder   |
| 02. Bipolar II disorder  |
| D. Anxiety disorders   |
| 01. Social anxiety   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| 02. Panic disorder  |
| 03. Generalized anxiety disorder                          |
| 04. Anxiety disorder due to another medical condition     |
| 05. Substance/medication-induced anxiety disorder         |
| XX. Other   |
| E. Obsessive-compulsive and related disorders             |
| F. Somatic symptom and related disorders                  |
| 01. Functional neurological disorder                      |
| 02. Pain disorder   |
| 03. Somatic symptom disorder                              |
| 04. Illness anxiety disorder                              |
| 05. Factitious disorders                                  |
| XX. Other   |
| G. Trauma- and stressor-related disorders                 |
| 01. Posttraumatic stress disorder                         |
| 02. Acute stress disorder                                 |
| 03. Adjustment disorder                                   |
| XX. Other   |
| H. Sexual disorders                                       |
| 01. Sexual pain disorders                                 |
| 02. Sexual dysfunction due to a general medical condition |
| 03. Other   |
| I. Feeding and eating disorders                           |
| 01. Anorexia nervosa                                      |
| 02. Bulimia nervosa                                       |
| J. Elimination disorders                                  |
| K. Personality disorders                                  |
| L. Neurobehavioral disorders                              |
| 01. Impulse-control and conduct disorders                 |
| M. Dissociative disorders (including fugue)               |
| XX. Other psychiatric disorders                           |
| <b>16. Autonomic nervous system disorders</b>             |
| A. Disorders of orthostatic tolerance                     |
| 01. Orthostatic hypotension                               |
| 02. Postural orthostatic tachycardia syndrome (POTS)      |
| 03. Neurally mediated syncope                             |
| a. Central causes (emotional)                             |
| b. Reflex causes  |
| i. Carotid sinus stimulation                              |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| ii. Micturition, defecation, coughing   |
| iii. Hemodynamic stress   |
| B. Autonomic dysfunction in CNS disorders   |
| 01. Lewy body disorders   |
| 02. Multiple system atrophy   |
| 03. Tauopathies   |
| 04. Pure autonomic failure  |
| 05. Multiple sclerosis  |
| 06. Stroke  |
| C. Disorders of sweating and thermoregulation   |
| 01. Hypothermia   |
| 02. Hyperthermia  |
| 03. Regional hyperhidrosis  |
| 04. Hypohidrosis (central and peripheral causes)  |
| D. Autonomic disorders of the urogenital system   |
| 01. Multiple sclerosis  |
| 02. Multiple system atrophy   |
| E. Autonomic disorders of the gastrointestinal tract  |
| 01. Achalasia   |
| 02. Gastroparesis   |
| 03. Cyclic vomiting syndrome  |
| 04. Intestinal pseudo-obstruction   |
| 05. Hirschsprung disease  |
| F. Visceral sensory disorders   |
| 01. Disorders of parasympathetic visceral sensation   |
| a. Disorders of taste   |
| b. Associated with glossopharyngeal neuralgia   |
| 02. Disorders of sympathetic visceral sensation (sympathetic storm in spinal cord transection, including autonomic dysreflexia) |
| 03. Disorders of central visceral sensation (insular cortex stroke)   |
| <b>17. Questions not associated with a specific neurologic disorder</b>   |
| A. Normal anatomy, process, neurophysiology   |
| B. Pharmacology   |
| C. Medical-legal, public policy/regulatory factors, professional practice   |
| D. Development through the life cycle: developmental processes, tasks, crises, transitions                                      |
| 01. Infancy   |
| 02. Childhood (school entry, peer relations, individuation)   |
| 03. Adulthood (employment, parenting, acquisition/loss of specific capacities)  |
| 04. Late life (cognition, physical endurance, loss of specific capacities)  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| E. Procedures/procedural safety  |
| F. Normal test results, findings, variants, artifacts, and methods   |
| <b>18. Neuroimmunologic and paraneoplastic CNS disorders</b>   |
| A. CNS vasculitis and microangiopathies  |
| 01. Primary angiitis of the CNS  |
| 02. Secondary CNS vasculitis   |
| a. Systemic vasculitides (giant cell arteritis, polyarteritis nodosa, microscopic polyangiitis, Behçet disease)    |
| b. Systemic autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, sarcoidosis) |
| c. Infectious vasculitis (varicella zoster)  |
| d. Substance-induced vasculitis (amphetamines, cocaine)  |
| 03. Microangiopathies (e.g., Susac syndrome, Sneddon syndrome)   |
| B. Neuroimmunologic/paraneoplastic CNS syndromes   |
| 01. Cerebellar syndromes   |
| 02. Encephalitis/encephalomyelitis (anti-NMDA, anti-IL2, limbic, other)  |
| 03. Opsoclonus-myoclonus   |
| 04. Epilepsy   |
| XX. Other  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| <b>Dimension 2</b>                              |  |
|---|--|
| <b>Physician Competencies and Mechanisms</b>    |  |
| <b>A. Neuroscience and mechanism of disease</b> |  |
| 01. Neuroanatomy                                |  |
| a.  | Cerebral cortex  |
| b.  | Connecting systems   |
| c.  | Basal ganglia/thalamus   |
| d.  | Brainstem  |
| e.  | Cerebellum   |
| f.  | Cranial nerves   |
| g.  | Spinal cord  |
| h.  | Spinal roots/peripheral nerves   |
| i.  | Ventricular system, CSF  |
| j.  | Vascular   |
| k.  | Neuromuscular junction/muscle  |
| l.  | Autonomic nervous system   |
| m.  | Embryology and neural development  |
| n.  | Pain pathways  |
| o.  | Radiologic anatomy, cerebral blood vessels (angiography or MRA)                                  |
| p.  | CSF anatomy, physiology, normal and abnormal patterns (cellular, chemical, enzymatic, serologic) |
| q.  | Meninges   |
| r.  | Plexus   |
| xx.   | Other  |
| 02. Neuropathology                              |  |
| a.  | Basic patterns of reaction   |
| b.  | Cerebrovascular disease  |
| c.  | Trauma (cranial and spinal)  |
| d.  | Metabolic/toxic/nutritional diseases   |
| e.  | Infections   |
| f.  | Demyelinating diseases/leukodystrophies  |
| g.  | Neoplasms  |
| h.  | Congenital/developmental anomalies   |
| i.  | Degenerative/heredodegenerative disorders  |
| j.  | Myopathies   |
| k.  | Peripheral nerve   |
| l.  | Neuromuscular junction disorders   |
| m.  | Radiologic pathology pertinent to assigned pathology sections                                    |
| n.  | Medium and large-vessel vasculitis   |
| xx.   | Other  |
| 03. Neurochemistry                              |  |
| a.  | Carbohydrate metabolism  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| b. Lipid metabolism  |
| c. Protein metabolism  |
| d. Neurotransmitters   |
| e. Axonal transport  |
| f. Energy metabolism   |
| g. Blood-brain barrier   |
| h. Biochemistry of membranes/receptors/ion channels                                    |
| i. Neuronal excitation   |
| j. Vitamins (general aspects)  |
| k. Inborn errors of metabolism   |
| l. Electrolytes and minerals   |
| m. Neurotoxins   |
| n. Free radical scavengers   |
| o. Excitotoxicity  |
| p. Normal CSF constituents and volume  |
| xx. Other  |
| <b>04. Neurophysiology</b>   |
| a. Membrane physiology   |
| b. Synaptic transmission   |
| c. Sensory receptors and perception  |
| d. Special senses  |
| e. Reflexes  |
| f. Segmental and suprasegmental control of movement                                    |
| g. Cerebellar function   |
| h. Reticular system: mechanisms of sleep and arousal, consciousness, circadian rhythms |
| i. Rhinencephalon, limbic system, visceral brain                                       |
| j. Learning and memory   |
| k. Cortical organization and function  |
| l. Cerebral blood flow   |
| m. Autonomic function  |
| n. Blood-brain barrier   |
| o. Neurophysiology of the visual system  |
| p. Neurophysiology of hearing and vestibular function                                  |
| q. Physiology of pain  |
| r. Physiology of peripheral nerve and muscle   |
| s. Coagulation cascade   |
| t. Metabolic and cellular consequences of ischemia                                     |
| u. Inflammation and stroke   |
| xx. Other  |
| <b>05. Neuroimmunology/neuroinfectious disease</b>                                     |
| a. Pathogenesis of multiple sclerosis  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |  |
|--|--|
| b.   | Pathogenesis of diseases (including prion diseases)                                    |
| c.   | Immunotherapy in multiple sclerosis, myasthenia gravis, and other neurologic disorders |
| d.   | Antibody mediated disorders  |
| xx.  | Other  |
| 06.  | Neurogenetics/molecular neurology, and neuroepidemiology                               |
| a.   | Mendelian-inherited diseases   |
| b.   | Other modes of inheritance   |
| c.   | Mitochondrial disorders  |
| d.   | Nucleotide repeat disorders  |
| e.   | Channelopathies  |
| f.   | Genetics of epilepsy   |
| g.   | Risk factors in neurologic disease   |
| h.   | Demographics of neurologic disease   |
| 07.  | Neuroendocrinology   |
| a.   | Thyroid gland  |
| b.   | Cushing syndrome   |
| c.   | Corticosteroids  |
| d.   | Growth hormones  |
| e.   | Hypothalamic function  |
| f.   | Adrenal gland  |
| g.   | Pituitary gland  |
| h.   | Prolactin  |
| i.   | Androgen   |
| j.   | Estrogen   |
| k.   | Progesterone   |
| 08.  | Pathophysiology  |
| a.   | Epilepsy   |
| b.   | Vascular   |
| c.   | Brain edema and increased ICP  |
| d.   | Neuromuscular  |
| xx.  | Other  |
| <b>B. Clinical aspects of neurologic disease</b> |  |
| 01.  | Epidemiology   |
| 02.  | Risk factors   |
| a.   | Risk factors for stroke  |
| b.   | Risk factors for epilepsy  |
| 03.  | Signs and symptoms   |
| 04.  | Comorbidities  |
| 05.  | Course of illness  |
| 06.  | Prognosis  |
| 07.  | Localization   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| 08. Pregnancy/peripartum   |
| 09. Complications of illness   |
| 10. Quality of life  |
| <b>C. Diagnostic procedures</b>  |
| 01. Neuroimaging   |
| a. Structural imaging (computed tomography, magnetic resonance imaging, and others)  |
| b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) |
| c. Functional neuroimaging, including fMRI, SPECT, PET, others   |
| 02. EEG (routine EEG, LTME, subdural and cortical EEGs)  |
| 03. Magnetoencephalography   |
| 04. Evoked potentials, including intraoperative monitoring   |
| 05. Sleep studies  |
| 06. EMG/NCS, including single fiber EMG (SFEMG)  |
| 07. Autonomic function testing   |
| 08. CSF examination/lumbar puncture  |
| 09. Laboratory studies   |
| 10. Neuropsychological and cognitive testing   |
| 11. Cardiac testing  |
| 12. Skin/nerve/muscle biopsy   |
| 13. Genetic testing  |
| 14. Neurophysiologic properties and instrumentation  |
| 15. Testing of special senses (e.g., hearing, vision)  |
| 16. Clinical/disease severity/rating scales  |
| 17. Pulmonary function test  |
| 18. Systemic imaging (e.g., CT, MRI, PET)  |
| 19. Metabolic testing  |
| 20. Special examination maneuvers  |
| XX. Other  |
| <b>D. Treatment/Management</b>   |
| 01. General principles of neuropharmacology  |
| a. Neuropharmacokinetics/neuropharmacodynamics   |
| b. Drug toxicity/adverse effects/idiosyncratic reactions/medication withdrawal/contraindications                             |
| c. Drug interactions   |
| d. Pregnancy   |
| i. Teratogenicity/neurodevelopmental effects in offspring  |
| ii. Drug level fluctuations  |
| iii. Breastfeeding   |
| e. Age, gender, and ethnicity issues   |
| f. Pharmacogenomics  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|  |
|--|
| g. Mechanisms of action  |
| h. Drug management decisions (initiation, continuation, discontinuation)                                     |
| 02. Pharmacotherapy  |
| a. Drugs for migraine and other headache syndromes   |
| b. Analgesics (nonnarcotic, narcotic, etc.)  |
| c. Antiseizure medications   |
| d. Drugs for sleep disorders   |
| e. Drugs for cerebrovascular disease, including antiplatelet agents, anticoagulants, and thrombolytics       |
| f. Drugs for neuromuscular disorders   |
| g. Drugs for movement disorders  |
| h. Drugs for multiple sclerosis (disease-modifying therapy and symptomatic treatment)                        |
| i. Drugs for psychiatric disorders (sedative-hypnotics, antianxiety agents, antidepressants, antipsychotics) |
| j. Vitamins/minerals/nutrients   |
| k. Immunomodulatory agents, including oral medications, prednisone, IV Ig, and plasma exchange               |
| l. Antimicrobial agents  |
| m. Drugs used for increased intracranial pressure and for brain/spinal cord edema                            |
| n. Drugs for autonomic dysfunctions  |
| o. Drugs for dementia/cognition/alertness  |
| p. Spasticity treatments   |
| q. Antineoplastic agents   |
| r. Monotherapy vs polytherapy  |
| s. Hormonal therapies  |
| xx. Other  |
| i. Sedation  |
| ii. Stimulants   |
| iii. Antidotes   |
| 03. Endovascular treatment   |
| 04. Neuromodulation  |
| a. Vagus nerve stimulation (VNS)   |
| b. Deep brain stimulation (DBS)  |
| c. Transcutaneous electrical nerve stimulation (TENS)  |
| d. Spinal cord stimulation (SCS)   |
| e. Transcranial magnetic stimulation (TMS)   |
| f. Electroconvulsive therapy (ECT)   |
| g. Responsive neurostimulation (RNS)   |
| xx. Other  |
| 05. Critical care  |
| 06. Surgical treatment/interventions/procedures  |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| 07. Radiation therapy   |
| 08. Rehabilitation  |
| a. Exercise   |
| b. Assistive devices  |
| c. Assistive technologies   |
| d. Braces   |
| e. Physical therapy and occupational therapy  |
| f. Pulmonary  |
| g. Speech/swallowing  |
| h. Nutrition management   |
| i. Principles of neurorehabilitation (e.g. regeneration and plasticity)   |
| j. Functional assessment  |
| k. Education  |
| l. Cognitive therapy  |
| m. Early intervention   |
| 09. Psychotherapy, biofeedback, behavioral therapy, etc.  |
| 10. Reassurance, observation, lifestyle modification, serial monitoring, etc.                                     |
| 11. Specific dietary treatment  |
| 12. Genetic counseling  |
| 13. Complications of management   |
| 14. Gene therapy/enzyme replacement therapy/stem cell replacement   |
| 15. Nonsurgical/nonpharmacological  |
| XX. Other   |
| <b>E. Interpersonal and communications skills</b>   |
| 01. Communication with patients   |
| a. Communication of progress  |
| 02. Communication with patients' families   |
| 03. Communication with other professionals  |
| 04. Communication with the healthcare team  |
| 05. Communication with the public   |
| 06. Management of conflict  |
| 07. Common errors in communication  |
| 08. Patient and family education  |
| <b>F. Professionalism</b>   |
| 01. Professional behavior   |
| 02. Adherence to ethical principles (e.g., informed consent, research issues, clinical care, admission of errors) |
| 03. Participation in the professional community   |
| 04. Sensitivity to diverse patient populations  |
| 05. End-of-life issues and brain death  |
| 06. Fatigue management/burnout  |
| <b>G. Practice-based learning and improvement</b>   |



## American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

|   |
|---|
| 01. Development and execution of lifelong learning                    |
| a. Self-assessment and self-improvement                               |
| b. Use of evidence-based guidelines                                   |
| c. Critical review of scientific literature                           |
| 02. Formal practice-based quality improvement                         |
| <b>H. Systems-based practice</b>                                      |
| 01. Patient safety and the healthcare team                            |
| a. Medical errors and their prevention                                |
| b. Communication in patient safety                                    |
| c. Regulatory and educational activities related to patient safety    |
| 02. Resource management   |
| a. Parity   |
| b. Access to care   |
| c. Negotiation with payers  |
| 03. Community-based care  |
| a. Community-based programs   |
| b. Prevention   |
| c. Recovery and rehabilitation  |
| d. Knowledge of the legal aspects of neurological practice            |
| 04. Referral for appropriate consultation/decision-making             |
| 05. Working with local and national disease-based and advocacy groups |